Single-cell RNA sequencing combined with artificial intelligence to uncover immunotherapy biomarkers and decipher drug resistance mechanisms in glioblastoma.
- 1Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
- 2Heilongjiang Provincial Hospital, Harbin, Heilongjiang, China.
- 3The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Abstract
Glioblastoma represents the most aggressive primary malignant tumor of the central nervous system, characterized by extensive intratumoral heterogeneity, profound immunosuppression, therapeutic resistance, and poor clinical outcomes. Although immunotherapy has revolutionized cancer treatment, its clinical efficacy in GBM remains limited, largely due to the complexity of the tumor ecosystem and the lack of validated predictive biomarkers. Recent advances in single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and artificial intelligence (AI)-based computational approaches have provided unprecedented opportunities to decipher tumor heterogeneity and identify clinically actionable biomarkers. This mini-review integrates studies related to scRNA-seq and its combination technology, further elaborating on the tumor plasticity, immune suppression, and metabolic-epigenetic reprogramming mechanisms of GBM. The article systematically summarizes the complete analysis process of integrating single-cell multi-omics data by AI and highlights the application value of AI in validating biomarkers. The above research ideas are expected to overcome clinical resistance problems, optimize patient stratification schemes, and enhance the efficacy of immunotherapy, providing theoretical support for developing highly stable prognostic biomarkers and achieving individualized precise immunotherapy for glioblastoma.
Related
- Artificial intelligence–enabled nursing surveillance for pediatric cancer immunotherapy: integrating biomarkers, patient-reported outcomes, and long-term toxicity management
- Toward Precision Colorectal Cancer Screening: Integrating Clinical Risk Stratification, Molecular Biomarkers, and Artificial Intelligence
- Vulnerable Coronary Plaques on CT Angiography: Imaging Biomarkers, Artificial Intelligence, and Emerging Technologies for Risk Stratification
- Circulating Biomarkers with Artificial Intelligence for Clinical Risk Assessment and Therapeutic Monitoring: Evidence, Limitations, and Translation
- Artificial intelligence-driven precision immunogenetics for cancer stem cell-targeted CAR immunotherapy
BibTeX
@article{fu2026singlecell,
title = {{Single-cell RNA sequencing combined with artificial intelligence to uncover immunotherapy biomarkers and decipher drug resistance mechanisms in glioblastoma.}},
author = {Tao Fu and Mengwan Hu and Xian Wu},
journal = {Frontiers in oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1970165},
url = {https://europepmc.org/article/MED/42899113},
note = {CC BY},
}
RIS
TY - JOUR
TI - Single-cell RNA sequencing combined with artificial intelligence to uncover immunotherapy biomarkers and decipher drug resistance mechanisms in glioblastoma.
AU - Tao Fu
AU - Mengwan Hu
AU - Xian Wu
PY - 2026
DA - 2026/10/05
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1970165
UR - https://europepmc.org/article/MED/42899113
AB - Glioblastoma represents the most aggressive primary malignant tumor of the central nervous system, characterized by extensive intratumoral heterogeneity, profound immunosuppression, therapeutic resistance, and poor clinical outcomes. Although immunotherapy has revolutionized cancer treatment, its clinical efficacy in GBM remains limited, largely due to the complexity of the tumor ecosystem and the lack of validated predictive biomarkers. Recent advances in single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and artificial intelligence (AI)-based computational approaches have provided unprecedented opportunities to decipher tumor heterogeneity and identify clinically actionable biomarkers. This mini-review integrates studies related to scRNA-seq and its combination technology, further elaborating on the tumor plasticity, immune suppression, and metabolic-epigenetic reprogramming mechanisms of GBM. The article systematically summarizes the complete analysis process of integrating single-cell multi-omics data by AI and highlights the application value of AI in validating biomarkers. The above research ideas are expected to overcome clinical resistance problems, optimize patient stratification schemes, and enhance the efficacy of immunotherapy, providing theoretical support for developing highly stable prognostic biomarkers and achieving individualized precise immunotherapy for glioblastoma.
SN - 2234-943X
ER -